INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
614Patents
598Active
614Granted
62Portfolio score
Filing activity: May 2, 1995 → Oct 2, 2024 · 70 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8574536B2 | Method to produce light-emitting nano-particles of diamond | Emerging Cross-Sectional Technologies | 62 | Active |
| US8741295B2 | PD-1 antibodies and PD-L1 antibodies and uses thereof | Chemistry; Metallurgy | 56 | Active |
| US6274711A | Purified mammalian CTLA-8 antigens and related reagents | Emerging Cross-Sectional Technologies | 49 | Expired |
| US7858081B2 | IL-15 mutants having agonists/antagonists activity | Human Necessities | 36 | Active |
| US9244059B2 | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease | Physics | 29 | Active |
| US9169316B2 | Production of antibody formats and immunological applications of said formats | Chemistry; Metallurgy | 23 | Active |
| US9376493B2 | Antibodies directed against ICOS and uses thereof | Chemistry; Metallurgy | 22 | Active |
| US6469155B1 | HIgR and related domain which binds glycoprotein D of herpes simplex virus | Human Necessities | 20 | Expired |
| US10293028B2 | Use of low dose IL-2 for treating autoimmune related or inflammatory disorders | Human Necessities | 19 | Active |
| US8802425B2 | Method for the hypothermic perfusion of a cardiac organ, and device for the implementation thereof | Human Necessities | 17 | Active |
| US9695446B2 | Direct protein delivery with engineered microvesicles | Chemistry; Metallurgy | 16 | Active |
| US9493533B2 | IL-15 mutants having antagonist activity | Human Necessities | 14 | Active |
| US8697439B2 | Direct protein delivery with engineered microvesicles | Chemistry; Metallurgy | 13 | Active |
| US6063372A | Uses of mammalian CTLA-8 and related reagents | Human Necessities | 12 | Expired |
| US9012221B2 | Method for producing platelets from megakaryocytes | Chemistry; Metallurgy | 11 | Active |
| US7833699B2 | Detection of tuberculosis and infection by Mycobacterium tuberculosis using HBHA | Physics | 10 | Active |
| US9724404B2 | HPV particles and uses thereof | Chemistry; Metallurgy | 10 | Active |
| US6716835B1 | Use of diltiazem for treating retinal pathologies | Human Necessities | 9 | Expired |
| US8895532B2 | Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous membranes | Human Necessities | 9 | Active |
| US9669071B2 | Method for stimulating T lymphocytes with IL-2 | Human Necessities | 9 | Active |
| US9593313B2 | 28 kDa GST proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a Th1 and/or Th17 response | Emerging Cross-Sectional Technologies | 8 | Active |
| US10688172B2 | HPV particles and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US8039445B2 | Methods and devices for delivering a therapeutic product to the ocular sphere of a subject | Human Necessities | 7 | Active |
| US6706870B2 | Nucleic acids encoding CTLA-8; and related reagents | Emerging Cross-Sectional Technologies | 7 | Expired |
| US9487782B2 | Methods for the treatment of leber congenital amaurosis | Emerging Cross-Sectional Technologies | 7 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.